• Deutsche Forschungsgemeinschaft (KO 1939/3-1): Pulmonary Embolism International Thrombolysis Study 3 (PEITHO-3): A reduced dose of intravenous thrombolytic treatment for patients with intermediate-high-risk acute pulmonary embolism (EudraCT: 2018-000816-96; NCT04430569); Status: recruiting
  • Boston Scientific (sponsor of the trial; global academic leadership and coordination by the CTH): The higher-risk pulmonary embolism thrombolysis study (HI-PEITHO): A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism (NCT04790370); Status: recruiting
  • Daiichi-Sankyo (DSE-DE-CV-20001): Filling the gaps of knowledge on healthcare outcomes during long-term anticoagulant treatment of pulmonary embolism (PE): Combined analysis of population data, phase III trials and phase IV studies; Status: analysis ongoing
  • Bayer AG: Follow-Up after Acute Pulmonary Embolism (FOCUS): a Prospective Observational Multicenter Cohort Study (German Clinical Trials registry: DRKS00005939); Status: recruitment terminated, analysis ongoing
  • Bayer AG: Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE): A prospective management trial (EudraCT: 2013-001657-28); Status: recruitment terminated, main results published
  • Boehringer Ingelheim (2015-2018): Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism: The  PEITHO-2 prospective management trial (EudraCT: 2015-001830-12; NCT02596555); Status: recruitment terminated, main results published